Table 1 Clinical, diagnostic and treatment data of patients with anti-N-methyl-D-aspartate receptor encephalitis
Patient number | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
Psychiatric symptoms | ++ | ++ | + | + | + | ++ |
Generalized Seizures | ++ | ++ | ++ | + | + | + |
Serum anti-NMDA receptor IgG titer | 1:320 | 1:1000 | - | 1:1000 | 1:800 | - |
CSF anti-NMDA receptor IgG titer | 1:10 | 1:100 | 1:10 | - | 1:100 | 1:100 |
CSF leukocytes/μl | 154 | 2 | 27 | 2 | 270 | 19 |
CSF oligoclonal bands | + | + | - | + | + | + |
MRI lesions | Hippocampal T2-hyper-intensities + bilateral diffusion elevation | - | unspecific | Subcortical T2-hyper-intensities + contrast enhance-ment | - | - |
Clinical onset to PET and treatment in months | 1 | 4 | 1 | 15 | 4 | 7 |
mRS at time of PET | 5 | 5 | 5 | 4 | 4 | 3 |
PET in propofol narcosis | + | + | + | + | + | - |
Intensive care treatment | + | + | + | - | + | - |
Methylprednisolone | + | + | + | + | + | + |
Plasmapheresis | + | + | - | + | + | - |
Immunoglobulins | + | + | + | - | - | - |
Immunosuppressive therapy | Rituxim. Cycloph. | Cycloph. | Rituxim. Cycloph. | Azathiopr. | Rituxim. Cycloph. | - |
Oophorectomy | + | + | + | + | + | - |
Ovarian teratoma | + | + | - | - | - | - |
mRS at follow up (months after PET) | 4 | 1 | 1 | 4 | 1 | 0 |
(40) | (40) | (28) | (8) | (16) | (36) |